ACCESS Newswire
10 May 2022, 19:43 GMT+10
DEA Fails It's Congressional Mandate To Facilitate FDA Marijuana Clinical Trials & Pharmaceutical Development For Suffering Patients
PROVIDENCE, RI / ACCESSWIRE / May 10, 2022 / Attorneys representing the MMJ biopharma conglomerate, a federal cannabis cultivation license applicant, filed a petition in federal court today, citing that the Drug Enforcement Agency (DEA) is taking too long to issue a determination for its application.
The company is further requesting 'declaratory and injunctive relief' as a result of the DEA's violation of the Administrative Procedures Act (APA) for the DEA's 'unreasonable delay in determining the outcome of its applications for registration for marihuana manufacturing and importing for it pending FDA sanctioned clinical trials.'
Yet this week the U.S. Food and Drug Administration( FDA) issued warning letters to dozens of companies for selling products labeled as containing delta-8 tetrahydrocannabinol (delta-8 THC) in ways that violate the Federal Food, Drug, and Cosmetic Act. This action is the first time the FDA has issued warning letters for products containing delta-8 THC. Delta-8 THC has psychoactive and intoxicating effects and may be dangerous to consumers. The FDA has received reports of CBD adverse events experienced by patients who have consumed these products, meanwhile the DEA drags its heals on legitimate scientific research to validate public health and safety.
Delta-8 THC is one of over 140 cannabinoids produced in the Cannabis plant that MMJ Biopharma Labs has studied in the lab. Concentrated amounts of delta-8 THC are typically manufactured from hemp-derived cannabidiol (CBD) and have psychoactive and intoxicating effects. Products containing delta-8-THC are available in varying forms, including but not limited to candy, cookies, breakfast cereal, chocolate, gummies, vape cartridges (carts), dabs, shatter, smokable hemp sprayed with delta-8-THC extract, distillate, tinctures, and infused beverages.
Dr. Elio Mariani, CEO of MMJ BioPharma Cultivation stated'In addition to addressing the illegal marketing of delta-8 THC products as unapproved treatments for medical conditions or other therapeutic uses, the FDA officials said in their release that the warning letters also cite violations related to the misbranding of drugs-such as not including adequate directions for use-and the addition of delta-8 in food products. MMJ proceed according to federal law to substantiate our claims by results of eventual FDA approved clinical trials.
Duane Boise, President and Founder of MMJ BioPharma continued that' the DEA has been an impediment to the much needed scientific research to validate efficacy by FDA. Multiple Sclerosis and Huntington's disease clinical trials of the cannabis derivatives of our medicines are on hold. We have completed our manufacturing of our gelatin capsule pill only to be stonewalled by the DEA in our process.'
Tim Moynahan, chairman of MMJ further stated 'MMJ continues its process of scientific drug
development and discovery by FDA protocols for the development processes, developing our intellectual
property portfolio and following the DEA regulatory manufacturing guidelines.
CONTACT:
Sara Parker
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
Get a daily dose of Memphis Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Memphis Sun.
More InformationGENEVA, Switzerland: A new United Nations report alleges that dozens of global corporations are profiting from and helping sustain...
LONDON, UK - Lawmakers in the United Kingdom have voted overwhelmingly to proscribe the direct-action group Palestine Action as a terrorist...
DHARAMSHALA, India: The Dalai Lama is set to address a significant three-day conference of Buddhist leaders this week, coinciding with...
WASHINGTON, D.C.: In a significant ruling last week, the U.S. Supreme Court upheld a Texas law requiring age verification for users...
ISTANBUL/PARIS/BRUSSELS: As searing temperatures blanket much of Europe, wildfires are erupting and evacuation orders are being issued...
VENICE, Italy: Over the weekend, hundreds of protesters marched through the narrow streets of Venice to voice their opposition to billionaire...
NEW YORK, New York -U.S. stock markets closed with broad gains on Thursday, led by strong performances in U.S. tech stocks, while European...
LONDON/STOCKHOLM: The Persson family is ramping up its investment in the H&M fashion empire, fueling renewed speculation about a potential...
PARIS, France: L'Oréal is making a fresh play in the booming premium haircare segment with a new acquisition. The French beauty conglomerate...
MENLO PARK, California: Robinhood is giving European investors a new way to tap into America's most prominent tech names — without...
NEW YORK, New York - U.S. stocks diverged on Wednesday for the second day in a row. The Standard and Poor's 500 hit a new all-time...
NEW YORK CITY, New York: The U.S. dollar continues to lose ground, weighed down by growing concerns over Washington's fiscal outlook...